MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 8, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that (OSI) Prosidion, its UK subsidiary focused on the discovery and development of diabetes and obesity therapeutics, reported positive preliminary results from a Phase IIa proof-of-concept and dose-range-finding study with its dipeptidyl peptidase-IV (DPIV) inhibitor, PSN9301. Following 14 days of therapy, PSN9301 substantially reduced glucose levels after an oral glucose tolerance test (OGTT) and was generally well tolerated with no episodes of hypoglycaemia. PSN9301 is scheduled to enter into Phase IIb clinical trials in mid-2006.
